Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
By temporarily suspending retinal activity in the non-amblyopic eye of animal models, neuroscientists restrengthened the visual response in the amblyopic eye, even at ages after the critical period when patch therapy fails.
The National Eye Institute has created a U.S.-Africa vision research collaboration with Nigeria’s National Eye Centre (NEC) to study children’s eye health.
Scientists studied the brain activity of school-aged children during development and found that regions that activated upon seeing limbs (hands, legs, etc.) subsequently activated upon seeing faces or words when the children grew older.
While it isn’t surprising that infants and children love to look at people’s movements and faces, recent research from Rochester Institute of Technology studies exactly where they look when they see someone using sign language.
New research shows how the mutation associated with Batten disease could potentially lead to degeneration of light sensing photoreceptor cells in the retina, and subsequent vision loss.
Children who undergo cataract surgery as infants have a 22% risk of glaucoma 10 years later, whether or not they receive an intraocular lens implant. The findings come from the National Eye Institute (NEI)-funded Infant Aphakic Treatment Study.
Children wearing multifocal contact lenses had slower progression of their myopia, according to results from a clinical trial funded by the National Eye Institute, part of the National Institutes of Health.
The NEI has funded development of a handheld pediatric vision scanner that easily and accurately screens for amblyopia, or “lazy eye.” The device could facilitate earlier identification of children who need vision-saving treatment.
Babies born prematurely who require treatment to prevent blindness from retinopathy of prematurity (ROP) could be treated with a dose of Avastin (bevacizumab) that is a fraction of the dose commonly used for ROP currently.
An artificial intelligence (AI) device that has been fast-tracked for approval by the Food and Drug Administration may help identify newborns at risk for aggressive posterior retinopathy of prematurity (AP-ROP). AP-ROP is the most severe form of ROP.
